Document › Details
PerkinElmer, Inc.. (7/12/16). "Press Release: PerkinElmer Prices Offering of Euro-denominated Senior Notes". Waltham, MA.
|Organisation||PerkinElmer Inc. (NYSE: PKI)|
|Organisation 2||J.P. Morgan Securities plc|
|Group||JPMorgan Chase (Group)|
|Product 2||laboratory equipment and instruments|
|Index term||PerkinElmer–SEVERAL: credit, 201607–2026 €500m 1.875% Senior Notes due 2026 at issue price of 99.118% of principal amount|
|Person||Thomas, Tommy J. (PerkinElmer 201501 Investor Relations Manager)|
|Person 2||Willinsky, Brian (PerkinElmer 201403)|
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, announced today that it has priced an offering of €500 million aggregate principal amount of 1.875% Senior Notes due 2026 at an issue price of 99.118% of the principal amount.
The issuance of the notes is expected to close on July 19, 2016, subject to customary closing conditions. The notes will pay interest on an annual basis.
PerkinElmer plans to use the net proceeds of the offering to reduce the amounts outstanding under its senior unsecured revolving credit facility and for general corporate purposes.
The joint book-running managers for the offering are J.P. Morgan Securities plc and Barclays Bank PLC.
The offering is being made pursuant to an effective registration statement on Form S-3 (including a prospectus) filed with the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the offering and the other documents that PerkinElmer has filed with the SEC for more complete information about the company and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus supplement and the accompanying prospectus relating to the offering can be obtained by calling J.P. Morgan Securities plc collect at +44 (0)207-134-246; or by calling Barclays Bank PLC toll-free at 1-888-603-5847.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
The prospectus in the registration statement and the prospectus supplement relating to the offering have been prepared on the basis that any offer of notes in any Member State of the European Economic Area (each, a "Member State") will be made pursuant to an exemption under Directive 2003/71/EC of the European Parliament and the Council of 4 November 2003 as amended (the "Prospectus Directive") from the requirement to publish a prospectus for offers of notes. Accordingly any person making or intending to make an offer in a Member State of notes which are the subject of the offering contemplated in the prospectus supplement may only do so in circumstances in which no obligation arises for PerkinElmer or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive, in each case, in relation to such offer. Neither we nor the joint book-running managers have authorized, nor do they authorize, the making of any offer of notes in circumstances in which an obligation arises for us or the underwriters to publish or supplement a prospectus for such offer.
The prospectus in the registration statement and the prospectus supplement relating to the offering are for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Market Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The prospectus in the registration statement and the prospectus supplement relating to the offering are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which such documents relate is available only to relevant persons and will be engaged in only with relevant persons.
Relevant stabilization regulations including ICMA apply.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.3 billion in 2015, has about 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about the company's intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the offering. Additional important factors and information regarding PerkinElmer's business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus and preliminary prospectus supplement dated July 12, 2016 related to the offering, which is on file with the SEC and available in the "Investors" section of our website under the heading "SEC Filings," and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Tommy J. Thomas, 781-663-5889
Brian Willinsky, 781-663-5728
Record changed: 2016-08-09
More documents for PerkinElmer (Group)
-  PerkinElmer, Inc.. (2/16/17). "Press Release: PerkinElmer to Present at Barclays Capital Global Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (2/2/17). "Press Release: PerkinElmer Announces Financial Results for Fourth Quarter and Full Year 2016". Waltham, MA....
-  PerkinElmer, Inc.. (1/23/17). "Press Release: PerkinElmer's NexION 2000 ICP-MS Provides Industry-leading Versatility for Trace Elemental Analyses". Waltham, MA....
-  PerkinElmer, Inc.. (1/9/17). "Press Release: PerkinElmer to Acquire Tulip Diagnostics Private Limited in India". Waltham, MA....
-  PerkinElmer, Inc.. (12/22/16). "Press Release: PerkinElmer to Sell Medical Imaging Business to Varian Medical Systems". Waltham, MA....
-  PerkinElmer, Inc.. (12/14/16). "Press Release: PerkinElmer to Present at J.P. Morgan 35th Annual Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/21/16). "Press Release: PerkinElmer to Present at Citi Global Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/14/16). "Press Release: PerkinElmer to Present at Piper Jaffray Healthcare Conference". Waltham, MA....
-  PerkinElmer, Inc.. (11/7/16). "Press Release: PerkinElmer Announces Financial Results for the Third Quarter of 2016". Waltham, MA....
-  PerkinElmer, Inc.. (10/26/16). "Press Release: PerkinElmer Board Declares Quarterly Dividend". Waltham, MA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]